Neutral · 64/100Jul 24, 6:59 AM EDT
MannKind Soars 5.7% Premarket on FDA Nod for Furoscix Auto-Injector and $50M Financing
MNKD
MannKind (MNKD) shares surged 5.7% premarket after the FDA approved Furoscix ReadyFlow™, a novel subcutaneous autoinjector for heart failure and chronic kidney disease that delivers IV-equivalent diuretic therapy. The company also announced a $50 million priva…
- ▹FDA approval of novel autoinjector for heart failure/kidney disease; platform technology with potential for pipeline expansion
- ▹Single-asset focus and dilution risk from $50M private placement cap upside
Neutral · 63/100Jul 24, 12:06 AM EDT
Scribe Therapeutics, Backed by Eli Lilly, Secures $128.7M in Upsized IPO at $15/Share
LLYSCTX
Scribe Therapeutics (SCTX) priced its upsized IPO at $15 per share, raising $128.7 million. The offering, backed by Eli Lilly (LLY), reflects strong investor demand for the gene-editing company as it prepares to trade on Nasdaq. This capital infusion supports…
- ▹Upsized IPO with Eli Lilly backing signals strong platform technology and BD interest
- ▹Pre-commercial stage with no approved products limits commercial and regulatory scores
Neutral · 55/100Jul 23, 10:41 PM EDT
Summit Therapeutics Sets November 14 FDA Decision Date for Ivonescimab; HARMONi-3 PFS Data Expected in 2H 2026
SMMT
Summit Therapeutics (SMMT) announced that the FDA has set a PDUFA date of November 14 for its ivonescimab BLA. The company also guided for HARMONi-3 progression-free survival data in the second half of 2026, as it prepares for potential commercialization.
- ▹PDUFA date set for November 14, 2025, with potential for accelerated approval; single-asset risk caps technology score.
- ▹Pre-commercialization planning and HARMONi-3 PFS readout in 2H 2026 provide positive narrative but limited near-term catalysts.
Neutral · 52/100Jul 24, 8:39 AM EDT
Vir Biotechnology CFO Steps Down, Interim Successor Named
VIR
Vir Biotechnology (VIR) announced that CFO Jason O'Byrne is departing to pursue another opportunity, effective July 23. Brent Sabatini, SVP and Chief Accounting Officer, has been appointed interim Principal Financial Officer. The leadership change may signal a…
- ▹CFO transition is a minor disruption, no impact on pipeline or regulatory status
- ▹Company has multiple assets but single-asset risk remains; narrative deduction for leadership change
High Risk · 48/100Jul 24, 7:54 AM EDT
AbbVie and Genmab's Epkinly Misses Primary Goal in Late-Stage Lymphoma Trial
ABBVGMAB
AbbVie (ABBV) and Genmab (GMAB) reported that their bispecific antibody epcoritamab (Epkinly) failed to achieve the primary endpoint in a Phase 3 trial for diffuse large B-cell lymphoma. The setback could impact future revenue expectations for the drug, which…
- ▹Failed Phase 3 trial for DLBCL, primary endpoint not met
- ▹Single-asset risk for Genmab, though AbbVie provides some diversification
High Risk · 42/100Jul 24, 9:00 AM EDT
Radiopharm Theranostics Raises $4.1M in US Direct Offering, Secures Up to A$12.7M in Australian Financing
RDPTFRADX
Radiopharm Theranostics (RADX, RDPTF) announced a $4.1M registered direct offering of 1.28M ADSs at $3.16 each, along with warrants. The company also secured up to A$12.7M in Australian financing, providing capital to advance its radiopharmaceutical pipeline.
- ▹Dilution risk from financing and warrants
- ▹Single-asset radiopharma company with no approved products
High Risk · 37/100Jul 24, 8:33 AM EDT
Dyadic International Back in Compliance with Nasdaq Listing Rules
DYAI
Dyadic International (DYAI) announced it has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b), ensuring its common stock remains listed on the Nasdaq Capital Market. Despite the positive compliance news, shares fell 6.92%. Investors should…
- ▹Regained Nasdaq compliance, removing delisting risk
- ▹Single-asset micro-cap with limited commercial revenue and short cash runway
High Risk · 32/100Jul 23, 5:34 PM EDT
Summit Therapeutics Flags Cash Shortfall, Risks Going Concern
SMMTJPM
Summit Therapeutics (SMMT) disclosed that its current cash and investments are insufficient to sustain operations for the next 12 months, raising going concern doubts. Shares fell ~5% after hours as investors react to the liquidity crunch, which could pressure…
- ▹Cash crunch threatens near-term viability
- ▹Single-asset micro-cap with no clear catalyst
High Risk · 27/100Jul 24, 8:23 AM EDT
NanoViricides Prices $3.8M Direct Offering, Stock Drops
NNVC
NanoViricides (NNVC) has entered into a securities purchase agreement for a $3.8M registered direct offering with an institutional investor, issuing 2.52M shares or pre-funded warrants plus additional warrants. The dilutive offering has pressured the stock pri…
- ▹Dilutive offering with no pipeline progress
- ▹Single-asset micro-cap with no revenue